266 related articles for article (PubMed ID: 12115176)
1. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.
Moreland LW; Alten R; Van den Bosch F; Appelboom T; Leon M; Emery P; Cohen S; Luggen M; Shergy W; Nuamah I; Becker JC
Arthritis Rheum; 2002 Jun; 46(6):1470-9. PubMed ID: 12115176
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis.
Quattrocchi E; Dallman MJ; Feldmann M
Arthritis Rheum; 2000 Aug; 43(8):1688-97. PubMed ID: 10943858
[TBL] [Abstract][Full Text] [Related]
3. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
[TBL] [Abstract][Full Text] [Related]
4. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis.
Bonelli M; Ferner E; Göschl L; Blüml S; Hladik A; Karonitsch T; Kiener HP; Byrne R; Niederreiter B; Steiner CW; Rath E; Bergmann M; Smolen JS; Scheinecker C
Arthritis Rheum; 2013 Mar; 65(3):599-607. PubMed ID: 23203906
[TBL] [Abstract][Full Text] [Related]
5. Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis.
Körmendy D; Hoff H; Hoff P; Bröker BM; Burmester GR; Brunner-Weinzierl MC
Arthritis Rheum; 2013 Jan; 65(1):81-7. PubMed ID: 23045162
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Nishimoto N; Yoshizaki K; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Hashimoto J; Azuma J; Kishimoto T
Arthritis Rheum; 2004 Jun; 50(6):1761-9. PubMed ID: 15188351
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.
Yocum DE; Furst DE; Kaine JL; Baldassare AR; Stevenson JT; Borton MA; Mengle-Gaw LJ; Schwartz BD; Wisemandle W; Mekki QA;
Arthritis Rheum; 2003 Dec; 48(12):3328-37. PubMed ID: 14673984
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4Ig blocks the development and progression of citrullinated fibrinogen-induced arthritis in DR4-transgenic mice.
Yue D; Brintnell W; Mannik LA; Christie DA; Haeryfar SM; Madrenas J; Chakrabarti S; Bell DA; Cairns E
Arthritis Rheum; 2010 Oct; 62(10):2941-52. PubMed ID: 20533540
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
Nuki G; Bresnihan B; Bear MB; McCabe D;
Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
[TBL] [Abstract][Full Text] [Related]
11. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
[TBL] [Abstract][Full Text] [Related]
12. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
[TBL] [Abstract][Full Text] [Related]
14. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides.
Moreland LW; Morgan EE; Adamson TC; Fronek Z; Calabrese LH; Cash JM; Markenson JA; Matsumoto AK; Bathon J; Matteson EL; Uramoto KM; Weyand CM; Koopman WJ; Heck LW; Strand V; Diveley JP; Carlo DJ; Nardo CJ; Richieri SP; Brostoff SW
Arthritis Rheum; 1998 Nov; 41(11):1919-29. PubMed ID: 9811045
[TBL] [Abstract][Full Text] [Related]
15. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.
Bonelli M; Göschl L; Blüml S; Karonitsch T; Hirahara K; Ferner E; Steiner CW; Steiner G; Smolen JS; Scheinecker C
Rheumatology (Oxford); 2016 Apr; 55(4):710-20. PubMed ID: 26672908
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
18. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.
Koenders MI; Marijnissen RJ; Joosten LA; Abdollahi-Roodsaz S; Di Padova FE; van de Loo FA; Dulos J; van den Berg WB; Boots AM
Arthritis Rheum; 2012 Jun; 64(6):1762-70. PubMed ID: 22213107
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.
Kondo H; Abe T; Hashimoto H; Uchida S; Irimajiri S; Hara M; Sugawara S
J Rheumatol; 2004 Feb; 31(2):243-51. PubMed ID: 14760792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
